Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 11;18(2):461–471. doi: 10.1038/s41423-020-00601-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B. A The level of serum total bile acid (TBA) in the sustained response (SR; n = 18) and nonresponse (NR; n = 19) groups of HBeAg-positive chronic hepatitis B (CHB) patients receiving pegylated interferon-alpha (PegIFNα) therapy. Mann–Whitney U test. B The number of SR and NR patients in the low TBA (n = 17) and high (n = 20) TBA groups. Chi-squared test. C The rate of HBeAg and HBsAg loss in the low TBA (n = 11) and high TBA (n = 7) groups in SR patients at the indicated time points after PegIFNα treatment. Two-way ANOVA. D Heatmap of serum BA profiles in SR and NR patients. E The level of BAs in the SR (n = 18) and NR (n = 19) groups. Mann–Whitney U test. F The level of BAs in the NR group relative to the SR group. G The number of SR and NR patients in the low taurocholic acid (TCA) group (n = 24) and high TCA group (n = 13). Chi-squared test. H The rate of HBeAg and HBsAg loss in the low TCA (n = 15) and high TCA (n = 3) groups in SR patients at the indicated time points after PegIFNα treatment. Two-way ANOVA. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001